Oral administration of genetically modified Bifidobacterium displaying HCV-NS3 multi-epitope fusion protein could induce an HCV-NS3-specific systemic immune response in mice

Vaccine

Volumn 32, Issue 25, 2014, Pages 3066-3074

  Takei, Saki ^a   Omoto, Chika ^b   Kitagawa, Koichi ^b   Morishita, Naoya ^a   Katayama, Takane ^c   Shigemura, Katsumi ^a   Fujisawa, Masato ^a   Kawabata, Masato ^a   Hotta, Hak ^a   Shirakawa, Toshiro ^a,b  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KOBE UNIVERSITY   (Japan)

^c ISHIKAWA PREFECTURAL UNIVERSITY   (Japan)

Author keywords

Bifidobacterium; HCV; Mucosal vaccine; NS3

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; GLBP NS3 FUSION PROTEIN; GST NS3 FUSION PROTEIN; HEPATITIS C VACCINE; HYBRID PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERLEUKIN 12; INTERLEUKIN 4; MESSENGER RNA; SECRETORY IMMUNOGLOBULIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BACTERIAL CELL; BIFIDOBACTERIUM LONGUM; CD8+ T LYMPHOCYTE; CELL ISOLATION; CELL SURFACE DISPLAY; CONTROLLED STUDY; DNA MODIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SPLEEN CELL; WESTERN BLOTTING;

BIFIDOBACTERIUM; HCV; MUCOSAL VACCINE; NS3;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, VIRAL; BIFIDOBACTERIUM; CYTOKINES; EPITOPES; FEMALE; HEPATITIS C; IMMUNITY, MUCOSAL; INTESTINES; MICE, INBRED BALB C; RECOMBINANT FUSION PROTEINS; SPLEEN; T-LYMPHOCYTES; VIRAL HEPATITIS VACCINES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84899994046     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.03.022     Document Type: Article

References (39)

1. World Health Organization Hepatitis C: global prevalence. Wkly Epidemiol Rec 1997, 72(46):341-348.
2. Bukh J., Purcell R.H., Miller R.H. Sequence analysis of the core gene of 14 hepatitis C virus genotypes. Proc Natl Acad Sci U S A 1994, 91(17):8239-8243.
3. Brody H. Hepatitis C. Nature 2011, 474(7350):S1-S7.
4. Li K., Lemon S.M. Innate immune responses in hepatitis C virus infection. Semin Immunopathol 2013, 35(1):53-72.
5. Di Bisceglie A.M., Hoofnagle J.H. Optimal therapy of hepatitis C. Hepatology 2002, 36(5 Suppl 1):S121-S127.
6. Flamm S.L., Lawitz E., Jacobson I., Bourlière M., Hezode C., Vierling J.M., et al. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. Clin Gastroenterol Hepatol 2013, 11(1):81-87.
7. Kumada H., Toyota J., Okanoue T., Chayama K., Tsubouchi H., Hayashi N. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012, 56(1):78-84.
8. Esteban R., Buti M. Triple therapy with boceprevir or telaprevir for treatment naïve HCV patients. Best Pract Res Clin Gastroenterol 2012, 26(4):445-453.
9. Torresi J., Johnson D., Wedemeyer H. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. J Hepatol 2011, 54(6):1273-1285.
10. Kolykhalov A.A., Mihalik K., Feinstone S.M., Rice C.M. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3' nontranslated region are essential for virus replication in vivo. J Virol 2000, 74(4):2046-2051.
11. Yu H., Babiuk L.A., van Drunen Littel-van den Hurk S. Priming with CpG-enriched plasmid and boosting with protein formulated with CpG oligodeoxynucleotides and Quil A induces strong cellular and humoral immune responses to hepatitis C virus NS3. J Gen Virol 2004, 85(Pt 6):1533-1543.
12. El-Gogo S., Staib C., Lasarte J.J., Sutter G., Adler H. Protective vaccination with hepatitis C virus NS3 but not core antigen in a novel mouse challenge model. J Gene Med 2008, 10(2):177-186.
13. Cerny A., McHutchison J.G., Pasquinelli C., Brown M.E., Brothers M.A., Grabscheid B., et al. Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J Clin Invest 1995, 95(2):521-530.
14. Candela M., Perna F., Carnevali P., Vitali B., Ciati R., Gionchetti P., et al. Interaction of probiotic Lactobacillus and Bifidobacterium strains with human intestinal epithelial cells: adhesion properties, competition against enteropathogens and modulation of IL-8 production. Int J Food Microbiol 2008, 125(3):286-292.
15. López P., Gueimonde M., Margolles A., Suárez A. Distinct Bifidobacterium strains drive different immune responses in vitro. Int J Food Microbiol 2010, 138(1-2):157-165.
16. Suzuki R., Wada J., Katayama T., Fushinobu S., Wakagi T., Shoun H., et al. Structural and thermodynamic analyses of solute-binding protein from Bifidobacterium longum specific for core 1 disaccharide and lacto-N-biose I. J Biol Chem 2008, 283(19):13165-13173.
17. Yamamoto S., Wada J., Katayama T., Jikimoto T., Nakamura M., Kinoshita S., et al. Genetically modified Bifidobacterium displaying Salmonella-antigen protects mice from lethal challenge of Salmonella Typhimurium in a murine typhoid fever model. Vaccine 2010, 28(41):6684-6691.
18. Matsumura H., Takeuchi A., Kano Y. Construction of Escherichia coli-Bifidobacterium longum shuttle vector transforming B. longum 105-A and 108-A. Biosci Biotechnol Biochem 1997, 61(7):1211-1212.
19. Lin C., Thomson J.A., Rice C.M. A central region in the hepatitis C virus NS4A protein allows formation of an active NS3-NS4A serine proteinase complex in vivo and in vitro. J Virol 1995, 69(7):4373-4380.
20. Yao N., Reichert P., Taremi S.S., Prosise W.W., Weber P.C. Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase. Structure 1999, 7(11):1353-1363.
21. Schulze zur Wiesch J., Lauer G.M., Day C.L., Kim A.Y., Ouchi K., Duncan J.E., et al. Broad repertoire of the CD4+ Th cell response in spontaneously controlled hepatitis C virus infection includes dominant and highly promiscuous epitopes. J Immunol 2005, 175(6):3603-3613.
22. Mashiba T., Udaka K., Hirachi Y., Hiasa Y., Miyakawa T., Satta Y., et al. Identification of CTL epitopes in hepatitis C virus by a genome-wide computational scanning and a rational design of peptide vaccine. Immunogenetics 2007, 59(3):197-209.
23. Wertheimer A.M., Miner C., Lewinsohn D.M., Sasaki A.W., Kaufman E., Rosen H.R. Novel CD4+ and CD8+ T-cell determinants within the NS3 protein in subjects with spontaneously resolved HCV infection. Hepatology 2003, 37(3):577-589.
24. Ito K., Shiraki K., Funatsuki K., Ishiko H., Sugimoto K., Murata K., et al. Identification of novel hepatitis C virus-specific cytotoxic T lymphocyte epiotpe in NS3 region. Hepatol Res 2006, 36(4):294-300.
25. López-Labrador F.X., He X.S., Berenguer M., Cheung R.C., Wright T.L., Greenberg H.B. The use of class-I HLA tetramers for the detection of hepatitis C virus NS3-specific CD8(+) T cells in patients with chronic infection. J Immunol Methods 2004, 287(1-2):91-99.
26. Neumann-Haefelin C., Frick D.N., Wang J.J., Pybus O.G., Salloum S., Narula G.S., et al. Analysis of the evolutionary forces in an immunodominant CD8 epitope in hepatitis C virus at a population level. J Virol 2008, 82(7):3438-3451.
27. Erickson A.L., Kimura Y., Igarashi S., Eichelberger J., Houghton M., Sidney J., et al. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunology 2001, 15(6):883-895.
28. Hidajat R., Nagano-Fujii M., Deng L., Tanaka M., Takigawa Y., Kitazawa S., et al. Hepatitis C virus NS3 protein interacts with ELKS-δ and ELKS-α, members of a novel protein family involved in intracellular transport and secretory pathways. J Gen Virol 2005, 86(Pt 8):2197-2208.
29. Chen Y.S., Hsiao Y.S., Lin H.H., Yen C.M., Chen S.C., Chen Y.L. Immunogenicity and anti-Burkholderia pseudomallei activity in Balb/c mice immunized with plasmid DNA encoding flagellin. Vaccine 2006, 24(6):750-758.
30. Strindelius L., Degling Wikingsson L., Sjöholm I. Extracellular antigens from Salmonella enteritidis induce effective immune response in mice after oral vaccination. Infect Immun 2002, 70(3):1434-1442.
31. Fu S., Xu J., Li X., Xie Y., Qiu Y., Du X., et al. Immunization of mice with recombinant protein CobB or AsnC confers protection against Brucella abortus infection. PLoS One 2012, 7(2):e29552.
32. Giudice E.L., Campbell J.D. Needle-free vaccine delivery. Adv Drug Deliv Rev 2006, 58(1):68-89.
33. Kim S.H., Lee K.Y., Jang Y.S. Mucosal Immune System and M Cell-targeting Strategies for Oral Mucosal Vaccination. Immune Netw 2012, 12(5):165-175.
34. Krishnadas D.K., Li W., Kumar R., Tyrrell D.L., Agrawal B. HCV-core and NS3 antigens play disparate role in inducing regulatory or effector T cells in vivo: implications for viral persistence or clearance. Vaccine 2010, 28(9):2104-2114.
35. Jiang W., Pisetsky D. Enhancing immunogenicity by CpG DNA. Curr Opin Mol Ther 2003, 5(2):180-185.
36. Raghavan S., Nystrom J., Fredriksson M., Holmgren J., Harandi A.M. Orally administered CpG oligodeoxynucleotide induces production of CXC and CC Chemokines in the gastric mucosa and suppresses bacterial colonization in a mouse model of Helicobacter pylori infection. Infect Immun 2003, 71(12):7014-7022.
37. Hosseini S.Y., Sabahi F., Moazzeni S.M., Modarressi M.H., Saberi Firoozi M., Ravanshad M. Construction and preparation of three recombinant adenoviruses expressing truncated NS3 and core genes of hepatitis C virus for vaccine purposes. Hepat Mon 2012, 12(8):e6130.
38. Sekiguchi S., Kimura K., Chiyo T., Ohtsuki T., Tobita Y., Tokunaga Y., et al. Immunization with a recombinant vaccinia virus that encodes nonstructural proteins of the hepatitis C virus suppresses viral protein levels in mouse liver. PLoS One 2012, 7(12):e51656.
39. Lang K.A., Yan J., Draghia-Akli R., Khan A., Weiner D.B. Strong HCV NS3- and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine. Vaccine 2008, 26(49):6225-6231.